tetano
Editor, Senior Moderator
Virol J
. 2023 Mar 27;20(1):53.
doi: 10.1186/s12985-023-02007-0.
Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies
Katerina Jazbec[SUP] 1 [/SUP], Mojca Jež[SUP] 2 [/SUP], Klemen Žiberna[SUP] 2 [/SUP], Polonca Mali[SUP] 2 [/SUP], Živa Ramšak[SUP] 3 [/SUP], Urška Rahne Potokar[SUP] 2 [/SUP], Zdravko Kvrzić[SUP] 2 [/SUP], Maja Černilec[SUP] 2 [/SUP], Melita Gracar[SUP] 2 [/SUP], Marjana Šprohar[SUP] 2 [/SUP], Petra Jovanovič[SUP] 2 [/SUP], Sonja Vuletić[SUP] 2 [/SUP], Primož Rožman[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Hyperimmune convalescent COVID-19 plasma (CCP) containing anti-SARS-CoV-2 neutralizing antibodies (NAbs) was proposed as a therapeutic option for patients early in the new coronavirus disease pandemic. The efficacy of this therapy depends on the quantity of neutralizing antibodies (NAbs) in the CCP units, with titers ≥ 1:160 being recommended. The standard neutralizing tests (NTs) used for determining appropriate CCP donors are technically demanding and expensive and take several days. We explored whether they could be replaced by high-throughput serology tests and a set of available clinical data.
Methods: Our study included 1302 CCP donors after PCR-confirmed COVID-19 infection. To predict donors with high NAb titers, we built four (4) multiple logistic regression models evaluating the relationships of demographic data, COVID-19 symptoms, results of various serological testing, the period between disease and donation, and COVID-19 vaccination status.
Results: The analysis of the four models showed that the chemiluminescent microparticle assay (CMIA) for the quantitative determination of IgG Abs to the RBD of the S1 subunit of the SARS-CoV-2 spike protein was enough to predict the CCP units with a high NAb titer. CCP donors with respective results > 850 BAU/ml SARS-CoV-2 IgG had a high probability of attaining sufficient NAb titers. Including additional variables such as donor demographics, clinical symptoms, or time of donation into a particular predictive model did not significantly increase its sensitivity and specificity.
Conclusion: A simple quantitative serological determination of anti-SARS-CoV-2 antibodies alone is satisfactory for recruiting CCP donors with high titer NAbs.
Keywords: Anti-SARS-CoV-2 antibodies; Antibody titer; COVID-19 convalescent plasma; Hyperimmune plasma donors; Neutralization assay.
. 2023 Mar 27;20(1):53.
doi: 10.1186/s12985-023-02007-0.
Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies
Katerina Jazbec[SUP] 1 [/SUP], Mojca Jež[SUP] 2 [/SUP], Klemen Žiberna[SUP] 2 [/SUP], Polonca Mali[SUP] 2 [/SUP], Živa Ramšak[SUP] 3 [/SUP], Urška Rahne Potokar[SUP] 2 [/SUP], Zdravko Kvrzić[SUP] 2 [/SUP], Maja Černilec[SUP] 2 [/SUP], Melita Gracar[SUP] 2 [/SUP], Marjana Šprohar[SUP] 2 [/SUP], Petra Jovanovič[SUP] 2 [/SUP], Sonja Vuletić[SUP] 2 [/SUP], Primož Rožman[SUP] 2 [/SUP]
Affiliations
- PMID: 36973781
- DOI: 10.1186/s12985-023-02007-0
Abstract
Background: Hyperimmune convalescent COVID-19 plasma (CCP) containing anti-SARS-CoV-2 neutralizing antibodies (NAbs) was proposed as a therapeutic option for patients early in the new coronavirus disease pandemic. The efficacy of this therapy depends on the quantity of neutralizing antibodies (NAbs) in the CCP units, with titers ≥ 1:160 being recommended. The standard neutralizing tests (NTs) used for determining appropriate CCP donors are technically demanding and expensive and take several days. We explored whether they could be replaced by high-throughput serology tests and a set of available clinical data.
Methods: Our study included 1302 CCP donors after PCR-confirmed COVID-19 infection. To predict donors with high NAb titers, we built four (4) multiple logistic regression models evaluating the relationships of demographic data, COVID-19 symptoms, results of various serological testing, the period between disease and donation, and COVID-19 vaccination status.
Results: The analysis of the four models showed that the chemiluminescent microparticle assay (CMIA) for the quantitative determination of IgG Abs to the RBD of the S1 subunit of the SARS-CoV-2 spike protein was enough to predict the CCP units with a high NAb titer. CCP donors with respective results > 850 BAU/ml SARS-CoV-2 IgG had a high probability of attaining sufficient NAb titers. Including additional variables such as donor demographics, clinical symptoms, or time of donation into a particular predictive model did not significantly increase its sensitivity and specificity.
Conclusion: A simple quantitative serological determination of anti-SARS-CoV-2 antibodies alone is satisfactory for recruiting CCP donors with high titer NAbs.
Keywords: Anti-SARS-CoV-2 antibodies; Antibody titer; COVID-19 convalescent plasma; Hyperimmune plasma donors; Neutralization assay.